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A 56-year-old man presented with anterior chamber inflammation, increased intraocular pressure, peripheral retinal 
infiltration, and generalized retinal arterial obstruction suggesting acute retinal necrosis five months after intravitreal 
triamcinolone acetonide injection (IVTA). He was treated with intravenous antiviral agents and aspirin. Shortly after 
treatment, retinal infiltrations were resolved, and partial recanalization of the obstructed vessel was observed. Viral 
retinitis may occur as an opportunistic infection following IVTA due to the local immune modulatory effect of the ste-
roid; hence, close observation following IVTA is necessary.
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Intravitreal injections of corticosteroid are recommended 
for a broad spectrum of ophthalmologic conditions. A benefi-
cial role of intravitreal steroid injections has been reported 
for diabetic macular edema, exudative age-related macular 
degeneration, macular edema secondary to retinal vein oc-
clusion, chronic uveitis, and pseudophakic cystoids macular 
edema [1,2].
Intravitreal steroid injections have potential complications, 
such as cataract development, increased intraocular pressure 
(IOP), retinal hemorrhage, retinal detachment, and endoph-
thalmitis [3]. Although steroids reduce local inflammation and 
retinal edema, they simultaneously decrease local defenses 
against pathologic agents [3-10]. Viral retinitis following intra-
vitreal triamcinolone acetonide injections (IVTAs) in im-
munocompetent patients has been reported [3-10], suggesting 
an association between intravitreal steroids and opportunistic 
infections. However, the association among intravitreal in-
jection of corticosteroid, viral retinitis, and the pathogenesis 
of viral retinitis has not been determined. In this report, we 
present a case of viral retinitis following IVTA in an im-
munocompetent patient and review the relevant literature.
Case Report
A 56-year-old man presented to our uveitis clinic for eval-
uation of a visual disturbance in his right eye. He had been di-
agnosed with diabetes four years previously and was control-
ling blood glucose with oral medications. His visual acuity 
was 20 / 40 in the right eye (OD) and 20 / 30 in the left eye. 
Fundus examination showed moderate non-proliferative dia-
betic retinopathy in both eyes and macular edema OD (Fig. 
1). The foveal thickness was 465 μm OD as observed by opti-
cal coherence tomography (OCT; Stratus OCT, Carl Zeiss 
Meditec, Dublin, CA, USA). We administered IVTA (4 mg) 
for treatment of the diabetic macular edema using an aseptic 
technique including irrigation of the conjunctival sac with di-
luted betadine solution and prescribed oral and topical anti-
biotics for one week after injection. After IVTA, the visual 
acuity improved to 20 / 32 OD and the macular edema de-
creased to 357 μm OD on OCT.
Five months after the IVTA, the patient returned to our 
clinic for right eye visual deterioration. The visual acuity was 
20 / 200 OD and the intraocular pressure was 23 mmHg according 
to Goldmann applanation tonometer (GAT) measurement. 
Slit lamp examination of the right eye revealed fine keratic 
precipitates on the corneal endothelium and moderate (grade 
+2 inflammatory cells) inflammation in the anterior chamber. 
Fundus examination showed severe generalized arterial ob-
struction, vitreous opacity, and a white necrotic retina in the 
inferotemporal periphery (Figs. 1B and 2A, black arrows). Korean J Ophthalmol Vol.25, No.6, 2011
452
A B
Fig. 1. Fundus photography of the right eye. (A) Before intravitreal injection of triamcinolone acetonide (IVTA), only mild diabetic changes 
can be seen. (B) Five months after IVTA, anterior chamber inflammation, severe arterial obstruction, and vitreous opacity developed.
A B
Fig. 2. Montage fundus photography. (A) Five months after intravitreal triamcinolone acetonide injection, anterior chamber inflammation, se-
vere arterial obstruction, and vitreous opacity developed. A white necrotic retinal area (black arrows) and vitreous opacity developed. 
Intravitreal triamcinolone is still visible in the inferior vitreous (white arrow). (B) After anti-viral treatment, the necrotic retinal area and vitre-
ous opacity were gradually resolved. One month after antiviral medication, the white retinal necrotic area eventually disappeared.
Remnant triamcinolone particles were still visible in the in-
ferior vitreous. (Fig. 2A, white arrow) After presumed diag-
nosis of viral retinitis, in particular acute retinal necrosis, lab-
oratory work-up, including anterior chamber paracentesis for 
viral polymerase chain reaction (PCR), was performed. 
However, no viral DNA was detected by PCR, including her-
pes simplex virus (HSV), varicella zoster virus (VZV), cyto-
megalovirus (CMV), or Ebstein-Barr virus. Blood tests for 
human immunodeficiency virus and syphilis were negative, 
and the CD4 cell count was within normal limits. Intravenous 
acyclovir was administered for ten days, and oral valaciclo-
vir was given for the following three weeks. Along with anti-
viral medications, oral aspirin and oral/topical steroids were 
prescribed. One week after initiation of antiviral medi-
cations, the size of the white retinal necrotic area decreased 
and eventually disappeared at one month (Fig. 2B). Barrier 
laser was performed around the necrotic retina for prevention 
of retinal breaks and detachment. After three months, blood 
samples for viral serology testing were collected. Anti-HSV, 
anti-CMV, and anti-VZV IgG were detected, but the IgM tit-
ers were negative. During routine six month follow-up visits, 
the visual acuity was limited to 20 / 100 OD due to cataract 
and epiretinal membrane (ERM). One year after the IVTA, 
vitrectomy for ERM removal combined with cataract oper-
ation was performed, and the visual acuity was restored to 20 
/ 40 OD. 
Discussion
Our case is presumed to be a form of acute retinal necrosisT
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(ARN) considering the prompt response to antiviral treatment, 
serum viral IgG results, and typical clinical presentations, 
although we failed to reveal the causative organism by PCR 
or serology. The causative association between IVTA and 
ARN was presumed by the visualization of triamcinolone 
particles at the time of ARN occurrence and no underlying 
systemic immune deficiency.
Other possible diagnoses include CMV retinitis and intra-
ocular lymphoma. In CMV retinitis, early lesions are located 
along the retinal blood vessels and sometimes on the fovea or 
disc. Intraocular lymphoma/leukemia could also produce 
whitish infiltrative subretinal lesions. However, in our case, 
ARN is the more likely diagnosis because a yellow-white ret-
inal lesion was initially noticed in the peripheral retina, and 
occlusive vasculopathy involving all retinal arteries was ob-
served with anterior chamber reactions, which are the patho-
gnomonic findings of ARN. Follow-up examination showed 
no evidence of lymphoma or leukemia.
To date, there are 12 case reports of necrotizing herpetic 
retinopathy, including nine of CMV retinitis and three of ARN 
in ten immunocompetent patients, of whom two immunocom-
promised patients received intravitreal corticosteroid in-
jections (Table 1) [3-11]. The mean age of patients with ne-
crotizing herpetic retinopathy associated with intravitreal 
corticosteroid injection ranged from 30 to 77 years (range, 
63.75 ± 14.13 years). PCR was performed for diagnosis of 
pathogens in all cases except one [6], which had a lack of vit-
reous due to previous vitrectomy. The diagnosis was con-
firmed in seven cases (63.6%) by detection of viral DNA. 
The IOP of the infected eye according to the available IOP 
data in case reports was 23 to 48 mmHg (mean, 32.8 ± 10.7 
mmHg). Elevated IOP is a common clinical feature of ne-
crotizing herpetic retinopathy associated with intravitreal 
corticosteroid injection. All case reports mentioned in-
flammatory cells in the anterior chamber. The interval be-
tween intravitreal corticosteroid injection and retinitis 
ranged from three weeks to seven months (range, 4.0 ± 1.7 
months).
Local immune deficiency by intravitreal steroid injections 
has been suggested as the most likely pathogenesis for ne-
crotizing herpetic retinopathy [3-10]. A history of viral reti-
nitis, such as CMV retinitis, was not clear except in only one 
case of CMV retinitis. However, reactivation of a virus from 
prior subclinical infections may play an important role in vi-
ral retinitis after IVTA, as well as in new viral infections.
Bacterial endophthalmitis, one of the most serious compli-
cations of an IVTA, presents 7.5 days after injection [12], 
which is earlier than that of necrotizing herpetic retinopathy 
(four months on average). Bacterial endophthalmitis usually 
develops through the inoculation of bacteria into the sterile 
vitreous, whereas necrotizing herpetic retinopathy can devel-
op by reactivation or by new inoculations. Beer et al. [13] re-
ported that triamcinolone was detected in the aqueous humor 
more than three months after IVTA. Moreover, triamcinolone 
can remain in the vitreous longer than in the aqueous humor 
[14]. The persistent immunocompromised state of the poste-
rior segment after IVTA appears to mimic the intraocular 
state of the immunocompromised patient and may be the 
main mechanism of viral retinitis, either by reactivation or by 
a new infection of a virus.
In conclusion, we report a case of presumed ARN after 
IVTA and propose that physicians should be aware of the 
possibility of necrotizing herpetic retinopathy after IVTA. 
Heightened suspicion and prompt treatment using antiviral 
agents could act to preserve visual acuity.
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